HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Learn more about:
Related Clinical Trial
Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis Cyclosporine A in the Treatment of Juvenile Idiopathic Arthritis (JIA) Associated Chronic Anterior Uveitis Screening for NEI Clinical Studies Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications HAT in Eye Complications of Behcet’s Disease Golimumab for the Treatment of Refractory Behcet’s Uveitis Tocilizumab for the Treatment of Refractory Behcet’s Uveitis Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis Interferon α2a Versus Cyclosporine for Refractory Behçet`s Disease Uveitis A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis Adalimumab vs. Conventional Immunosuppression for Uveitis Trial Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB) Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Quality of Life and Visual Function in Uveitis Patients Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Brief Title

HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Official Title

HUMIRA® Special Investigation (Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis)

Brief Summary

      This study evaluates the long- term safety and effectiveness of adalimumab in participants
      with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.
    



Study Type

Observational


Primary Outcome

Incidence of adverse drug reactions (ADR)

Secondary Outcome

 Change in Visual Functioning Questionnaire (VFQ)-25 score

Condition

Uveitis


Study Arms / Comparison Groups

 Participants receiving adalimumab
Description:  Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

259

Start Date

November 15, 2016

Completion Date

October 14, 2020

Primary Completion Date

October 14, 2020

Eligibility Criteria

        Inclusion Criteria:

          -  Participants receiving adalimumab for the treatment of Non-infectious Intermediate-,
             Posterior-, or Pan-uveitis

        Exclusion Criteria:

          -  Participants previously treated with adalimumab
      

Gender

All

Ages

N/A - 100 Years

Accepts Healthy Volunteers

No

Contacts

AbbVie Inc., , 

Location Countries

Japan

Location Countries

Japan

Administrative Informations


NCT ID

NCT02916017

Organization ID

P15-665


Responsible Party

Sponsor

Study Sponsor

AbbVie


Study Sponsor

AbbVie Inc., Study Director, AbbVie


Verification Date

October 2020